{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:58:02Z","timestamp":1789091882318,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,7]]},"DOI":"10.7759\/cureus.50118","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T16:01:24Z","timestamp":1701964884000},"source":"Crossref","is-referenced-by-count":4,"title":["The Influence of Coffee on Reducing Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: A Review"],"prefix":"10.7759","author":[{"given":"Manpreet","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmathi","family":"Murugesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachpreet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine N","family":"Uy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasjeet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navina","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajneet K","family":"Sekhon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach","volume":"28","author":"Le MH","year":"2022","unstructured":"Le MH, Yeo YH, Zou B, Barnet S, Henry L, Cheung R, Nguyen MH. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol. 2022, 28:841-50. 10.3350\/cmh.2022.0239","journal-title":"Clin Mol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2019.07.015","article-title":"Non-alcoholic fatty liver disease after liver transplantation in patients with non-alcoholic steatohepatitis and cryptogenic cirrhosis: the impact of pre-transplant graft steatosis","volume":"22","author":"Eshraghian A","year":"2020","unstructured":"Eshraghian A, Nikeghbalian S, Kazemi K, Shamsaeefar A, Geramizadeh B, Malek-Hosseini SA. Non-alcoholic fatty liver disease after liver transplantation in patients with non-alcoholic steatohepatitis and cryptogenic cirrhosis: the impact of pre-transplant graft steatosis. HPB (Oxford). 2020, 22:521-8. 10.1016\/j.hpb.2019.07.015","journal-title":"HPB (Oxford)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000820","article-title":"Nonalcoholic steatohepatitis recurrence and rate of fibrosis progression following liver transplantation","volume":"29","author":"Sourianarayanane A","year":"2017","unstructured":"Sourianarayanane A, Arikapudi S, McCullough AJ, Humar A. Nonalcoholic steatohepatitis recurrence and rate of fibrosis progression following liver transplantation. Eur J Gastroenterol Hepatol. 2017, 29:481-7. 10.1097\/MEG.0000000000000820","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.10.008","article-title":"Lifestyle modification in NAFLD\/NASH: facts and figures","volume":"1","author":"Hallsworth K","year":"2019","unstructured":"Hallsworth K, Adams LA. Lifestyle modification in NAFLD\/NASH: facts and figures. JHEP Rep. 2019, 1:468-79. 10.1016\/j.jhepr.2019.10.008","journal-title":"JHEP Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/BF00146266","article-title":"Unexpected effects of coffee consumption on liver enzymes","volume":"9","author":"Casiglia E","year":"1993","unstructured":"Casiglia E, Spolaore P, Ginocchio G, Ambrosio GB. Unexpected effects of coffee consumption on liver enzymes. Eur J Epidemiol. 1993, 9:293-7. 10.1007\/BF00146266","journal-title":"Eur J Epidemiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/advances\/nmx007","article-title":"Practical dietary recommendations for the prevention and management of nonalcoholic fatty liver disease in adults","volume":"9","author":"George ES","year":"2018","unstructured":"George ES, Forsyth A, Itsiopoulos C, et al.. Practical dietary recommendations for the prevention and management of nonalcoholic fatty liver disease in adults. Adv Nutr. 2018, 9:30-40. 10.1093\/advances\/nmx007","journal-title":"Adv Nutr"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5024","article-title":"Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes","volume":"359","author":"Poole R","year":"2017","unstructured":"Poole R, Kennedy OJ, Roderick P, Fallowfield JA, Hayes PC, Parkes J. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. BMJ. 2017, 359:j5024. 10.1136\/bmj.j5024","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12970","article-title":"Coffee intake protects against symptomatic gallstone disease in the general population: a Mendelian randomization study","volume":"287","author":"Nordestgaard AT","year":"2020","unstructured":"Nordestgaard AT, Stender S, Nordestgaard BG, Tybjaerg-Hansen A. Coffee intake protects against symptomatic gallstone disease in the general population: a Mendelian randomization study. J Intern Med. 2020, 287:42-53. 10.1111\/joim.12970","journal-title":"J Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi ZM","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, et al.. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019, 71:793-801. 10.1016\/j.jhep.2019.06.021","journal-title":"J Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options","volume":"1","author":"Gastaldelli A","year":"2019","unstructured":"Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep. 2019, 1:312-28. 10.1016\/j.jhepr.2019.07.002","journal-title":"JHEP Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/lifemeta\/load007","article-title":"Type 2 diabetes originated from non-alcoholic fatty liver disease","volume":"2","author":"Xiong X","year":"2023","unstructured":"Xiong X, Li X. Type 2 diabetes originated from non-alcoholic fatty liver disease. Life Metab. 2023, 2:load007. 10.1093\/lifemeta\/load007","journal-title":"Life Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00064.2004","article-title":"Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population","volume":"288","author":"Szczepaniak LS","year":"2005","unstructured":"Szczepaniak LS, Nurenberg P, Leonard D, et al.. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005, 288:E462-8. 10.1152\/ajpendo.00064.2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al.. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023, 78:1966-86. 10.1097\/HEP.0000000000000520","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-3902-y","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"59","year":"2016","unstructured":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016, 59.1121-40. 10.1007\/s00125-016-3902-y","journal-title":"Diabetologia"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-Sppc","article-title":"Professional Practice Committee: standards of medical care in diabetes-2020","volume":"43","year":"2020","unstructured":"Professional Practice Committee. standards of medical care in diabetes-2020. Diabetes Care. 2020, 43:S3. 10.2337\/dc20-Sppc","journal-title":"Diabetes Care"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni G","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006, 6:33. 10.1186\/1471-230X-6-33","journal-title":"BMC Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee JH","year":"2010","unstructured":"Lee JH, Kim D, Kim HJ, et al.. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010, 42:503-8. 10.1016\/j.dld.2009.08.002","journal-title":"Dig Liver Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15830","article-title":"Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices","volume":"52","author":"Younossi ZM","year":"2020","unstructured":"Younossi ZM, Corey KE, Alkhouri N, et al.. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther. 2020, 52:513-26. 10.1111\/apt.15830","journal-title":"Aliment Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.12.034","article-title":"Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population","volume":"20","author":"Graupera I","year":"2022","unstructured":"Graupera I, Thiele M, Serra-Burriel M, et al.. Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clin Gastroenterol Hepatol. 2022, 20:2567-2576.e6. 10.1016\/j.cgh.2021.12.034","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10030159","article-title":"Non-alcoholic fatty liver disease in patients with type 2 diabetes: evaluation of hepatic fibrosis and steatosis using Fibroscan","volume":"10","author":"Tuong TT","year":"2020","unstructured":"Tuong TT, Tran DK, Phu PQ, Hong TN, Dinh TC, Chu DT. Non-alcoholic fatty liver disease in patients with type 2 diabetes: evaluation of hepatic fibrosis and steatosis using Fibroscan. Diagnostics (Basel). 2020, 10:10.3390\/diagnostics10030159","journal-title":"Diagnostics (Basel)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309265","article-title":"Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study","volume":"65","author":"Kwok R","year":"2016","unstructured":"Kwok R, Choi KC, Wong GL, et al.. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016, 65:1359-68. 10.1136\/gutjnl-2015-309265","journal-title":"Gut"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/cld.740","article-title":"Con: liver biopsy remains the gold standard to evaluate fibrosis in patients with nonalcoholic fatty liver disease","volume":"13","author":"Berger D","year":"2019","unstructured":"Berger D, Desai V, Janardhan S. Con: liver biopsy remains the gold standard to evaluate fibrosis in patients with nonalcoholic fatty liver disease. Clin Liver Dis (Hoboken). 2019, 13:114-6. 10.1002\/cld.740","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i2.475","article-title":"Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Sumida Y","year":"2014","unstructured":"Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J Gastroenterol. 2014, 20:475-85. 10.3748\/wjg.v20.i2.475","journal-title":"World J Gastroenterol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.04.025","article-title":"Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study","volume":"165","author":"Huang DQ","year":"2023","unstructured":"Huang DQ, Wilson LA, Behling C, et al.. Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study. Gastroenterology. 2023, 165:463-472.e5. 10.1053\/j.gastro.2023.04.025","journal-title":"Gastroenterology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1021\/ja105512f","article-title":"Comprehensive natural products II: chemistry and biology, volumes 1-10","volume":"132","author":"Mander L","year":"2010","unstructured":"Mander L, Liu HW. Comprehensive natural products II: chemistry and biology, volumes 1-10. J Am Chem Soc. 2010, 132:9929. 10.1021\/ja105512f","journal-title":"J Am Chem Soc"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/BF00609587","article-title":"Plasma and salivary pharmacokinetics of caffeine in man","volume":"21","author":"Newton R","year":"1981","unstructured":"Newton R, Broughton LJ, Lind MJ, Morrison PJ, Rogers HJ, Bradbrook ID. Plasma and salivary pharmacokinetics of caffeine in man. Eur J Clin Pharmacol. 1981, 21:45-52. 10.1007\/BF00609587","journal-title":"Eur J Clin Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1986.tb05247.x","article-title":"Quantitative assessment of caffeine partial clearances in man","volume":"22","author":"Lelo A","year":"1986","unstructured":"Lelo A, Miners JO, Robson RA, Birkett DJ. Quantitative assessment of caffeine partial clearances in man. Br J Clin Pharmacol. 1986, 22:183-6. 10.1111\/j.1365-2125.1986.tb05247.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00217-013-2140-5","article-title":"Antimicrobial effect and mode of action of chlorogenic acid on Staphylococcus aureus","volume":"238","author":"Li G","year":"2013","unstructured":"Li G, Wang X, Xu Y, Zhang B, Xia X. Antimicrobial effect and mode of action of chlorogenic acid on Staphylococcus aureus. Eur Food Res Technol. 2013, 238:589-96. 10.1007\/s00217-013-2140-5","journal-title":"Eur Food Res Technol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1021\/jf5026983","article-title":"Effect of exogenous amylolytic enzymes on the accumulation of chlorogenic acid isomers in wounded potato tubers","volume":"62","author":"Torres-Contreras AM","year":"2014","unstructured":"Torres-Contreras AM, Nair V, Cisneros-Zevallos L, Jacobo-Vel\u00e1zquez DA. Effect of exogenous amylolytic enzymes on the accumulation of chlorogenic acid isomers in wounded potato tubers. J Agric Food Chem. 2014, 62:7671-5. 10.1021\/jf5026983","journal-title":"J Agric Food Chem"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphotobiol.2013.11.020","article-title":"Chlorogenic acid-phospholipid complex improve protection against UVA induced oxidative stress","volume":"130","author":"Bhattacharyya S","year":"2014","unstructured":"Bhattacharyya S, Majhi S, Saha BP, Mukherjee PK. Chlorogenic acid-phospholipid complex improve protection against UVA induced oxidative stress. J Photochem Photobiol B. 2014, 130:293-8. 10.1016\/j.jphotobiol.2013.11.020","journal-title":"J Photochem Photobiol B"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/131.1.66","article-title":"Chlorogenic acid and caffeic acid are absorbed in humans","volume":"131","author":"Olthof MR","year":"2001","unstructured":"Olthof MR, Hollman PC, Katan MB. Chlorogenic acid and caffeic acid are absorbed in humans. J Nutr. 2001, 131:66-71. 10.1093\/jn\/131.1.66","journal-title":"J Nutr"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/133.6.1806","article-title":"Chlorogenic acid, quercetin-3-rutinoside and black tea phenols are extensively metabolized in humans","volume":"133","author":"Olthof MR","year":"2003","unstructured":"Olthof MR, Hollman PC, Buijsman MN, van Amelsvoort JM, Katan MB. Chlorogenic acid, quercetin-3-rutinoside and black tea phenols are extensively metabolized in humans. J Nutr. 2003, 133:1806-14. 10.1093\/jn\/133.6.1806","journal-title":"J Nutr"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201300349","article-title":"Dose-response plasma appearance of coffee chlorogenic and phenolic acids in adults","volume":"58","author":"Renouf M","year":"2014","unstructured":"Renouf M, Marmet C, Giuffrida F, et al.. Dose-response plasma appearance of coffee chlorogenic and phenolic acids in adults. Mol Nutr Food Res. 2014, 58:301-9. 10.1002\/mnfr.201300349","journal-title":"Mol Nutr Food Res"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/diseases6030080","article-title":"Potential therapeutic benefits of herbs and supplements in patients with NAFLD","volume":"6","author":"Perumpail BJ","year":"2018","unstructured":"Perumpail BJ, Li AA, Iqbal U, et al.. Potential therapeutic benefits of herbs and supplements in patients with NAFLD. Diseases. 2018, 6:10.3390\/diseases6030080","journal-title":"Diseases"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X15593700","article-title":"Association between caffeine consumption and nonalcoholic fatty liver disease: a systemic review and meta-analysis","volume":"9","author":"Shen H","year":"2016","unstructured":"Shen H, Rodriguez AC, Shiani A, Lipka S, Shahzad G, Kumar A, Mustacchia P. Association between caffeine consumption and nonalcoholic fatty liver disease: a systemic review and meta-analysis. Therap Adv Gastroenterol. 2016, 9:113-20. 10.1177\/1756283X15593700","journal-title":"Therap Adv Gastroenterol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/nu15010004","article-title":"Increased intake of both caffeine and non-caffeine coffee components is associated with reduced NAFLD severity in subjects with type 2 diabetes","volume":"15","author":"Coelho M","year":"2022","unstructured":"Coelho M, Patarr\u00e3o RS, Sousa-Lima I, et al.. Increased intake of both caffeine and non-caffeine coffee components is associated with reduced NAFLD severity in subjects with type 2 diabetes. Nutrients. 2022, 15:10.3390\/nu15010004","journal-title":"Nutrients"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/s12937-021-00694-5","article-title":"Effects of supplementation with main coffee components including caffeine and\/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled, clinical trial","volume":"20","author":"Mansour A","year":"2021","unstructured":"Mansour A, Mohajeri-Tehrani MR, Samadi M, et al.. Effects of supplementation with main coffee components including caffeine and\/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Nutr J. 2021, 20:35. 10.1186\/s12937-021-00694-5","journal-title":"Nutr J"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/nu11092074","article-title":"Efficacy of arabica versus robusta coffee in improving weight, insulin resistance, and liver steatosis in a rat model of type-2 diabetes","volume":"11","author":"Shokouh P","year":"2019","unstructured":"Shokouh P, Jeppesen PB, Christiansen CB, Mellbye FB, Hermansen K, Gregersen S. Efficacy of arabica versus robusta coffee in improving weight, insulin resistance, and liver steatosis in a rat model of type-2 diabetes. Nutrients. 2019, 11:10.3390\/nu11092074","journal-title":"Nutrients"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.17179\/excli2019-2021","article-title":"Short term effects of coffee components consumption on gut microbiota in patients with non-alcoholic fatty liver and diabetes: a pilot randomized placebo-controlled, clinical trial","volume":"19","author":"Mansour A","year":"2020","unstructured":"Mansour A, Mohajeri-Tehrani MR, Karimi S, et al.. Short term effects of coffee components consumption on gut microbiota in patients with non-alcoholic fatty liver and diabetes: a pilot randomized placebo-controlled, clinical trial. EXCLI J. 2020, 19:241-50. 10.17179\/excli2019-2021","journal-title":"EXCLI J"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10010084","article-title":"Bifidobacterium bifidum shows more diversified ways of relieving non-alcoholic fatty liver compared with Bifidobacterium adolescentis","volume":"10","author":"Wang L","year":"2021","unstructured":"Wang L, Jiao T, Yu Q, et al.. Bifidobacterium bifidum shows more diversified ways of relieving non-alcoholic fatty liver compared with Bifidobacterium adolescentis. Biomedicines. 2021, 10:10.3390\/biomedicines10010084","journal-title":"Biomedicines"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1272\/jnms.JNMS.2024_91-102","article-title":"Molecular mechanisms of macroautophagy, microautophagy, and chaperone-mediated autophagy","author":"Yamamoto H","year":"2023","unstructured":"Yamamoto H, Matsui T. Molecular mechanisms of macroautophagy, microautophagy, and chaperone-mediated autophagy. J Nippon Med Sch. 2023, 10.1272\/jnms.JNMS.2024_91-102","journal-title":"J Nippon Med Sch"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2018.03.042","article-title":"Hypoxia, oxidative stress and inflammation","volume":"125","author":"McGarry T","year":"2018","unstructured":"McGarry T, Biniecka M, Veale DJ, Fearon U. Hypoxia, oxidative stress and inflammation. Free Radic Biol Med. 2018, 125:15-24. 10.1016\/j.freeradbiomed.2018.03.042","journal-title":"Free Radic Biol Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-15-0602-4_3","article-title":"Regulation of autophagy by mTOR signaling pathway","volume":"1206","author":"Wang Y","year":"2019","unstructured":"Wang Y, Zhang H. Regulation of autophagy by mTOR signaling pathway. Adv Exp Med Biol. 2019, 1206:67-83. 10.1007\/978-981-15-0602-4_3","journal-title":"Adv Exp Med Biol"},{"key":"ref44","article-title":"The cell: a molecular approach. 2nd edition","author":"Cooper GM","year":"2000","unstructured":"Cooper GM. The cell: a molecular approach. 2nd edition. Sinauer Associates, Sunderland, MA; 2000."},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108863","article-title":"Autophagy in major human diseases","volume":"40","author":"Klionsky DJ","year":"2021","unstructured":"Klionsky DJ, Petroni G, Amaravadi RK, et al.. Autophagy in major human diseases. EMBO J. 2021, 40:e108863. 10.15252\/embj.2021108863","journal-title":"EMBO J"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-8684-7_10","article-title":"Autophagy, NAFLD and NAFLD-related HCC","volume":"1061","author":"Wu WK","year":"2018","unstructured":"Wu WK, Zhang L, Chan MT. Autophagy, NAFLD and NAFLD-related HCC. Adv Exp Med Biol. 2018, 1061:127-38. 10.1007\/978-981-10-8684-7_10","journal-title":"Adv Exp Med Biol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2015.1038685","article-title":"Autophagy and apoptosis in liver injury","volume":"14","author":"Wang K","year":"2015","unstructured":"Wang K. Autophagy and apoptosis in liver injury. Cell Cycle. 2015, 14:1631-42. 10.1080\/15384101.2015.1038685","journal-title":"Cell Cycle"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2014.11.005","article-title":"Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis","volume":"1","author":"Hirsova P","year":"2015","unstructured":"Hirsova P, Gores GJ. Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis. Cell Mol Gastroenterol Hepatol. 2015, 1:17-27. 10.1016\/j.jcmgh.2014.11.005","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.14305","article-title":"Molecular regulation of autophagy machinery by mTOR-dependent and -independent pathways","volume":"1467","author":"Al-Bari MA","year":"2020","unstructured":"Al-Bari MA, Xu P. Molecular regulation of autophagy machinery by mTOR-dependent and -independent pathways. Ann N Y Acad Sci. 2020, 1467:3-20. 10.1111\/nyas.14305","journal-title":"Ann N Y Acad Sci"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2016.02.010","article-title":"Structure and function of the ULK1 complex in autophagy","volume":"39","author":"Lin MG","year":"2016","unstructured":"Lin MG, Hurley JH. Structure and function of the ULK1 complex in autophagy. Curr Opin Cell Biol. 2016, 39:61-8. 10.1016\/j.ceb.2016.02.010","journal-title":"Curr Opin Cell Biol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e08-12-1248","article-title":"Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy","volume":"20","author":"Hosokawa N","year":"2009","unstructured":"Hosokawa N, Hara T, Kaizuka T, et al.. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell. 2009, 20:1981-91. 10.1091\/mbc.e08-12-1248","journal-title":"Mol Biol Cell"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.4161\/auto.2788","article-title":"Insulin htts on autophagy","volume":"2","author":"Lumeng CN","year":"2006","unstructured":"Lumeng CN, Saltiel AR. Insulin htts on autophagy. Autophagy. 2006, 2:250-3. 10.4161\/auto.2788","journal-title":"Autophagy"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.2337\/db21-0281","article-title":"Nutrient sensor mTORC1 regulates insulin secretion by modulating \u03b2-cell autophagy","volume":"71","author":"Israeli T","year":"2022","unstructured":"Israeli T, Riahi Y, Garzon P, et al.. Nutrient sensor mTORC1 regulates insulin secretion by modulating \u03b2-cell autophagy. Diabetes. 2022, 71:453-69. 10.2337\/db21-0281","journal-title":"Diabetes"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-018-1028-5","article-title":"Knockdown of insulin-like growth factor 1 exerts a protective effect on hypoxic injury of aged BM-MSCs: role of autophagy","volume":"9","author":"Yang M","year":"2018","unstructured":"Yang M, Wen T, Chen H, Deng J, Yang C, Zhang Z. Knockdown of insulin-like growth factor 1 exerts a protective effect on hypoxic injury of aged BM-MSCs: role of autophagy. Stem Cell Res Ther. 2018, 9:284. 10.1186\/s13287-018-1028-5","journal-title":"Stem Cell Res Ther"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-020-0260-9","article-title":"How does mTOR sense glucose starvation? AMPK is the usual suspect","volume":"6","author":"Leprivier G","year":"2020","unstructured":"Leprivier G, Rotblat B. How does mTOR sense glucose starvation? AMPK is the usual suspect. Cell Death Discov. 2020, 6:27. 10.1038\/s41420-020-0260-9","journal-title":"Cell Death Discov"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020818","article-title":"Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed APOE((-\/-)) mice by activating autophagy and reducing ER stress and apoptosis","volume":"22","author":"Nasiri-Ansari N","year":"2021","unstructured":"Nasiri-Ansari N, Nikolopoulou C, Papoutsi K, et al.. Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed APOE((-\/-)) mice by activating autophagy and reducing ER stress and apoptosis. Int J Mol Sci. 2021, 22:10.3390\/ijms22020818","journal-title":"Int J Mol Sci"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26667","article-title":"Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice","volume":"59","author":"Sinha RA","year":"2014","unstructured":"Sinha RA, Farah BL, Singh BK, et al.. Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice. Hepatology. 2014, 59:1366-80. 10.1002\/hep.26667","journal-title":"Hepatology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/176778-the-influence-of-coffee-on-reducing-metabolic-dysfunction-associated-steatotic-liver-disease-in-patients-with-type-2-diabetes-a-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:09:27Z","timestamp":1707509367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/176778-the-influence-of-coffee-on-reducing-metabolic-dysfunction-associated-steatotic-liver-disease-in-patients-with-type-2-diabetes-a-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":57,"URL":"https:\/\/doi.org\/10.7759\/cureus.50118","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,7]]}}}